Assessment of Visual Function and Optics in Intraocular Lenses

July 20, 2023 updated by: Aston University

Evaluating Subjective and Objective Performance of Instrumentation Used and Devices Implanted in Cataract Surgery

The main objective of this research is to assess visual function and optical performance of CE marked, implanted intraocular lenses to understand the individual factors that affect their performance and how these may be improved in future designs and to evaluate measurement techniques.

All outcome measures will be captured 3-6 months after surgery

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

A cataract occurs when the natural lens of the eye, which plays a major role in the focusing of light and production of sharp visual images, becomes cloudy and hardens, resulting in a loss of visual function. Left untreated, cataracts can cause preventable blindness. During cataract surgery the natural lens is removed and a man-made intraocular lens (IOL) is implanted in its place.

IOL technology has advanced significantly in recent years and as a result the main goal of cataract surgery is no longer simply the successful removal of the cloudy lens and restoration of vision. Providing patients with the best possible refractive outcome and the best possible visual quality is now much more important when assessing surgery outcomes.

Aspheric, multifocal and accommodating IOLs are among the new designs developed to improve visual outcome after cataract surgery. In order to assess the effectiveness of these designs, visual function needs to be evaluated both objectively and subjectively following their implantation. Such evaluation allows the continued evolution of these IOL designs towards optimum. This proposed research study, which aims to assess the visual function and optical performance of new CE marked IOLs after implantation, could significantly contribute to the enhancement and development of improved IOL designs in the future.

We have successfully conducted similar patient trials for the past 5 years. As new IOL designs are constantly being developed, approved and CE marked, this type of research study will always have the potential to offer new information that is not currently available and has not previously been assessed or published and could contribute towards improved IOL designs in the future.

All outcome measures will be captured 3-6 months after surgery

Study Type

Interventional

Enrollment (Estimated)

500

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Midlands
      • Birmingham, West Midlands, United Kingdom, B18 7QH
        • Birmingham Midland Eye Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

38 years to 83 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Subjects age between 40-85 years, may be either male or female, and may be of any race (as cataracts rarely occur before the age of 40 and above 85 other ocular pathology is common).
  • Subjects requiring cataract surgery.
  • Potential for best corrected visual acuity of 6/12 or better (as visual function in these patients will be affected by ocular pathology).
  • Subjects with clear intraocular media other than cataract (as assessing cataract).
  • General physical and mental condition allowing participation in current study.
  • Subjects willing to participate as evidenced by signing the written informed

Exclusion Criteria:

  • Prior surgery on the selected eye
  • Previous uveitis or trauma to the selected eye, anterior or posterior synechiae
  • Potential for best corrected visual acuity worse than 6/12 (since this may indicate other causes of ocular pathology)
  • Partial or total paralysis, Parkinsons syndrome, cerebrovascular accident or other condition that could impact on the results of the study
  • Subject over 85 years of age (ocular pathology more common in this age group)
  • Subjects without adequate physical and mental capacity to enable participation in the study
  • Subject unwilling to participate
  • Systemic or topical medication known to influence visual function measures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Monofocal

Monofocal IOL Implant

Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

Monofocal Intraocular lens will be implanted
Other Names:
  • Alcon AMO B&L Lenstec Oculentis Ophthec Physiol & Zeiss
Experimental: Multifocal

Multifocal IOL

Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

Multifocal IOL will be implanted
Experimental: Toric

Toric IOL

Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss

Toric IOLS will be implanted

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Unaided distance and near vision
Time Frame: Measured at 3-6 months after surgery
Visual Acuity (logMAR)
Measured at 3-6 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Satisfaction
Time Frame: Measured at 3-6 months after surgery
NAVQ score
Measured at 3-6 months after surgery
Residual refraction
Time Frame: Measured at 3-6 months after surgery
Autorefraction / subjective refraction
Measured at 3-6 months after surgery
Aberrations
Time Frame: Measured at 3-6 months after surgery
Aberrometry
Measured at 3-6 months after surgery
Corrected distance and near acuity
Time Frame: Measured at 3-6 months after surgery
Acuity (logMAR)
Measured at 3-6 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sunil Shah, FRCS, Birmingham Midland Eye Centre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2013

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

July 17, 2012

First Submitted That Met QC Criteria

July 30, 2012

First Posted (Estimated)

July 31, 2012

Study Record Updates

Last Update Posted (Actual)

July 21, 2023

Last Update Submitted That Met QC Criteria

July 20, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IOL2012

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data collaboration will be considered on request

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Monofocal IOL

3
Subscribe